The cost-effectiveness of varicella vaccination in Canada

Vaccine

Volumn 20, Issue 7-8, 2002, Pages 1113-1125

  Brisson, M ^a,b   Edmunds, W J ^a,b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b CITY UNIVERSITY   (United Kingdom)

Author keywords

Cost effectiveness; Economic analysis; Mathematical modeling; Varicella vaccine; VZV; Zoster

Indexed keywords

CHICKENPOX VACCINE; VARICELLA ZOSTER VACCINE;

ADOLESCENCE; ARTICLE; CANADA; CHICKENPOX; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; HEALTH; HEALTH PROGRAM; HERPES ZOSTER; HUMAN; INFANT; MAJOR CLINICAL STUDY; MODEL; MORBIDITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY ANALYSIS; VACCINATION;

ADOLESCENT; ADULT; AGED; CANADA; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; HERPES ZOSTER; HUMANS; INFANT; INFANT, NEWBORN; MIDDLE AGED; VACCINATION;

EID: 0037081542     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00437-6     Document Type: Article

References (52)

1. The nature of herpes zoster: A long-term study and a new hypothesis
2. Epidemiology of varicella and zoster in Canada and the United Kingdom
3. Varicella vaccine
4. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales
5. The epidemiology of varicella-zoster virus infections: A mathematical model
6. The epidemiology of varicella-zoster virus infections: The influence of varicella on the prevalence of herpes-zoster
7. Population-based studies of varicella complications
8. Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: Retrospective controlled study and review
9. Is smoking a risk factor for pneumonia in adults with chickenpox?
10. Age-specific risks of varicella complications
11. Herpes zoster and its complications in Italy: An observational survey
12. Population-based study of herpes zoster and its sequelae
13. Postherpetic neuralgia
14. The outcome of patients with herpes zoster
15. Live attenuated varicella vaccine
16. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine
17. Analysis of varicella vaccine breakthrough rates: Implications for the effectiveness of immunisation programmes
18. Modelling the impact of immunisation on the epidemiology of varicella zoster virus
19. Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles
20. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States
21. Cost-effectiveness of a routine varicella vaccination program for US children
22. Costs and Benefits of routine varicella vaccination in Geman children
23. The cost-effectiveness of varicella vaccine programs for Australia
24. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule
25. A cost benefit analysis of routine varicella vaccination in Spain
26. Varicella: Complications and costs
27. Childhood vaccination against chickenpox: An analysis of benefits and costs
28. The value of varicella vaccination in healthy children: Cost-benefit analysis of the situation in France
29. An age-structured model of pre- and post-vaccination measles transmission
30. Chaos and biological complexity in measles dynamics
31. Predicting the impact of measles vaccination in England and Wales: Model validation and analysis of policy options
32. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations
33. Cost of chickenpox in Canada. I. Cost of uncomplicated cases
34. Cost of chickenpox in Canada. II. Cost of complicated cases and total economic impact
35. The immunization monitoring program-active (IMPACT) prospective surveillance of varicella zoster infections among hospitalised Canadian children: 1991-1996
36. Varicella mortality: Trends before vaccine licensure in the United States, 1970-1994
37. Direct costs attributed to chickenpox and herpes zoster in British Columbia: 1992-1996
38. Post-licensure safety surveillance for varicella vaccine
39. The cost of childhood chickenpox: Parents' perspective
40. Cost of varicella in France: A study in day care centers
41. Epidemiology and cost analysis of varicella in Italy: Results of a sentinel study in the pediatric practice
42. Impact of chickenpox on households of healthy children
43. Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine
44. Post-licensure effectiveness of varicella vaccine during an outbreak in a child care center
45. Epidemiology of primary varicella and herpes zoster hospitalisations: The pre-varicell vaccine era